{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.5","upperLimit":"41.8","value":"30.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"CRR assessed by investigators according to Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)","id":"OG000","title":"R/R ENKTL"}],"paramType":"NUMBER","populationDescription":"One patient was excluded from the efficacy analysis set because the patient was not confirmed as ENKTL by central pathology.","reportingStatus":"POSTED","timeFrame":"From enrollment to end of follow-up, a median of 29 months","title":"Complete Response Rate (CRR) by Investigators","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}